Published in Bioorg Med Chem Lett on January 20, 2010
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
Chemoselective Synthesis of Polysubstituted Pyridines from Heteroaryl Fluorosulfates. Chemistry (2016) 0.78
Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists. ACS Med Chem Lett (2013) 0.75
Site-selective Suzuki-Miyaura coupling of heteroaryl halides - understanding the trends for pharmaceutically important classes. Chem Sci (2016) 0.75
Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits. Mol Cell Biol (2003) 1.12
Social audit of provincial health services: building the community voice into planning in South Africa. J Interprof Care (2004) 1.01
Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. J Med Chem (2007) 0.86
Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation? Ann N Y Acad Sci (2002) 0.86
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem (2008) 0.81
Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. J Med Chem (2009) 0.81
CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem (2007) 0.80
Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode. Bioorg Med Chem Lett (2011) 0.79
Pyrazine-based Syk kinase inhibitors. Bioorg Med Chem Lett (2012) 0.79
Highly potent aminopyridines as Syk kinase inhibitors. Bioorg Med Chem Lett (2012) 0.78
New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists. Bioorg Med Chem Lett (2006) 0.78
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. J Med Chem (2011) 0.77
Discovery of a novel class of zwitterionic, potent, selective and orally active S1P₁ direct agonists. Bioorg Med Chem Lett (2012) 0.77
1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem (2009) 0.77
Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement. Bioorg Med Chem Lett (2010) 0.77
A new chemical tool (C0036E08) supports the role of adenosine A(2B) receptors in mediating human mast cell activation. Biochem Pharmacol (2008) 0.76
Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J Med Chem (2006) 0.75
Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists. Eur J Med Chem (2010) 0.75
Novel triazolopyridylbenzamides as potent and selective p38α inhibitors. Bioorg Med Chem Lett (2012) 0.75
Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines. Bioorg Med Chem (2008) 0.75
Phosphodiesterase 7A1 is expressed in human CD4+ naïve T cells at higher levels than in CD4+ memory cells and is not required during their CD3/CD28-dependent activation. Cell Immunol (2006) 0.75